Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 5 | 2018 | 345 | 1.590 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2018 | 56 | 1.050 |
Why?
|
| Eosinophilia | 2 | 2018 | 47 | 0.870 |
Why?
|
| Interleukin-13 | 2 | 2018 | 16 | 0.820 |
Why?
|
| Food Hypersensitivity | 2 | 2018 | 20 | 0.550 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2013 | 234 | 0.510 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 186 | 0.490 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2013 | 92 | 0.450 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 43 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 511 | 0.430 |
Why?
|
| Dermatitis, Atopic | 1 | 2010 | 17 | 0.360 |
Why?
|
| Immunoglobulin E | 1 | 2010 | 91 | 0.360 |
Why?
|
| Anti-Allergic Agents | 1 | 2010 | 27 | 0.360 |
Why?
|
| Network Meta-Analysis | 2 | 2018 | 5 | 0.330 |
Why?
|
| Interleukin-5 | 2 | 2018 | 14 | 0.330 |
Why?
|
| Interleukin-4 | 2 | 2018 | 69 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 1026 | 0.310 |
Why?
|
| Azithromycin | 1 | 2007 | 13 | 0.290 |
Why?
|
| Drug Compounding | 1 | 2007 | 34 | 0.280 |
Why?
|
| Delayed-Action Preparations | 1 | 2007 | 120 | 0.280 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 938 | 0.270 |
Why?
|
| Receptors, IgE | 1 | 2005 | 22 | 0.250 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2005 | 18 | 0.250 |
Why?
|
| Mycoses | 1 | 2005 | 60 | 0.240 |
Why?
|
| Antifungal Agents | 1 | 2005 | 108 | 0.240 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 151 | 0.230 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2003 | 12 | 0.230 |
Why?
|
| Dermatologic Agents | 1 | 2003 | 32 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2005 | 215 | 0.220 |
Why?
|
| Tacrolimus | 1 | 2003 | 127 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 239 | 0.200 |
Why?
|
| Sinusitis | 1 | 2005 | 432 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2020 | 7028 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 13 | 0.160 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 12 | 0.160 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 26 | 0.160 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 43 | 0.160 |
Why?
|
| Humans | 13 | 2020 | 68549 | 0.150 |
Why?
|
| Administration, Topical | 2 | 2010 | 111 | 0.150 |
Why?
|
| Risk Factors | 3 | 2020 | 5720 | 0.130 |
Why?
|
| Rhinitis | 1 | 2020 | 383 | 0.130 |
Why?
|
| Administration, Inhalation | 1 | 2013 | 187 | 0.110 |
Why?
|
| Colostrum | 1 | 2012 | 6 | 0.110 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2012 | 13 | 0.110 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2012 | 12 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2013 | 304 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 41 | 0.100 |
Why?
|
| Adult | 5 | 2018 | 21379 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 772 | 0.100 |
Why?
|
| Patient Safety | 1 | 2013 | 202 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2018 | 2004 | 0.100 |
Why?
|
| Age Factors | 2 | 2018 | 1860 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.100 |
Why?
|
| Milk, Human | 1 | 2012 | 147 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 43 | 0.090 |
Why?
|
| Omalizumab | 1 | 2010 | 24 | 0.090 |
Why?
|
| Incidence | 1 | 2013 | 1582 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2018 | 3187 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.080 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2007 | 5 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 59 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1851 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 946 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2007 | 90 | 0.070 |
Why?
|
| Female | 6 | 2018 | 38021 | 0.070 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2005 | 4 | 0.070 |
Why?
|
| Infant | 3 | 2018 | 2891 | 0.070 |
Why?
|
| Male | 6 | 2018 | 37283 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2005 | 19 | 0.070 |
Why?
|
| Adolescent | 3 | 2018 | 8904 | 0.070 |
Why?
|
| Bronchial Provocation Tests | 1 | 2005 | 9 | 0.060 |
Why?
|
| Beclomethasone | 1 | 2005 | 4 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2005 | 13 | 0.060 |
Why?
|
| Eosinophils | 1 | 2005 | 60 | 0.060 |
Why?
|
| Child | 2 | 2018 | 6401 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 260 | 0.060 |
Why?
|
| Dermatitis, Toxicodendron | 1 | 2003 | 2 | 0.060 |
Why?
|
| Pruritus | 1 | 2003 | 35 | 0.060 |
Why?
|
| United States | 2 | 2018 | 7338 | 0.060 |
Why?
|
| Exanthema | 1 | 2003 | 30 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 507 | 0.060 |
Why?
|
| Aspirin | 1 | 2005 | 295 | 0.060 |
Why?
|
| Time Factors | 2 | 2018 | 4655 | 0.050 |
Why?
|
| Aged | 2 | 2011 | 14842 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 514 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1738 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2020 | 33 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 1329 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 248 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2018 | 51 | 0.040 |
Why?
|
| Pedigree | 1 | 2018 | 159 | 0.040 |
Why?
|
| Protein Domains | 1 | 2018 | 74 | 0.040 |
Why?
|
| Middle Aged | 3 | 2005 | 21119 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 137 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2018 | 230 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 174 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 951 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2018 | 57 | 0.040 |
Why?
|
| Medicaid | 1 | 2018 | 301 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 329 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1082 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 597 | 0.030 |
Why?
|
| Intradermal Tests | 1 | 2012 | 3 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2455 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2356 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1054 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 5710 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 2334 | 0.020 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2005 | 2 | 0.020 |
Why?
|
| Nocardia asteroides | 1 | 2005 | 4 | 0.020 |
Why?
|
| Nocardia Infections | 1 | 2005 | 8 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 2005 | 27 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 62 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 3703 | 0.020 |
Why?
|